[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 30 of about 30
1. Aloysius MM, Zaitoun AM, Bates TE, Ilyas M, Constantin-Teodosiu D, Rowlands BJ, Lobo DN: Immunohistochemical expression of mitochondrial membrane complexes (MMCs) I, III, IV and V in malignant and benign periampullary epithelium: a potential target for drug therapy of periampullary cancer? BMC Cancer; 2010;10:80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of mitochondrial membrane complexes (MMCs) I, III, IV and V in malignant and benign periampullary epithelium: a potential target for drug therapy of periampullary cancer?
  • METHODS: This was a retrospective study on tissue microarrays constructed from formalin-fixed paraffin-embedded tissue from 126 consecutive patients (cancer = 104, chronic pancreatitis = 22) undergoing pancreatic resections between June 2001 and June 2006.
  • 78 specimens of chronic pancreatitis tissue were obtained adjacent to areas of cancer.
  • Normal pancreatic tissue was obtained from the resection specimens in a total of 30 patients.
  • Metastatic tumours in 61 regional lymph nodes from 61 patients were also studied.
  • RESULTS: MMCs I, III, IV and V were highly expressed (p < 0.05) in all primary periampullary cancers compared with metastatic lymph nodes and adjacent benign pancreas.
  • MMCs III, IV and V were highly expressed in all cancers regardless of type compared with chronic pancreatitis (p < 0.05).
  • Higher expression of MMCs I and V was associated with better survival and may, in part, relate to lower expression of these MMCs in poorly differentiated tumours compared with well and moderately differentiated tumours.
  • CONCLUSIONS: Differential expression of MMCs III, IV and V in primary periampullary cancers compared with adjacent benign periampullary tissue and chronic pancreatitis is a novel finding, which may render them attractive anticancer targets.
  • [MeSH-minor] Adult. Aged. Cell Proliferation. Epithelium / drug effects. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Metastasis. Oxidative Stress. Pancreas / pathology. Pancreatitis / pathology. Phosphorylation. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2000 Aug 18;289(5482):1150-1 [10970229.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Breast Cancer Res Treat. 2001 Jul;68(1):9-19 [11678313.001]
  • [Cites] Toxicol Appl Pharmacol. 2001 Nov 1;176(3):145-52 [11714246.001]
  • [Cites] Cell. 2003 Feb 21;112(4):481-90 [12600312.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2003 Jul;285(1):L189-98 [12665464.001]
  • [Cites] Trends Mol Med. 2004 Aug;10(8):372-8 [15310457.001]
  • [Cites] BMJ. 2004 Sep 18;329(7467):668-73 [15374918.001]
  • [Cites] Cancer. 1993 Dec 15;72(12):3641-7 [8252480.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1309-12 [9721092.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Mar 11;328(2):623-32 [15694394.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1606-25 [15887154.001]
  • [Cites] Biochem Pharmacol. 2005 Jul 1;70(1):1-12 [15907809.001]
  • [Cites] Cell Metab. 2005 Jun;1(6):401-8 [16054089.001]
  • [Cites] Nat Rev Cancer. 2005 Nov;5(11):857-66 [16327764.001]
  • [Cites] Oncogene. 2006 Aug 7;25(34):4787-97 [16892091.001]
  • [Cites] Oncogene. 2006 Aug 7;25(34):4812-30 [16892093.001]
  • [Cites] Exp Physiol. 2006 Sep;91(5):807-19 [16857720.001]
  • [Cites] FEBS Lett. 2006 Oct 2;580(22):5125-9 [16979626.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Mar 2;354(1):50-5 [17214968.001]
  • [Cites] J Bioenerg Biomembr. 2007 Feb;39(1):65-72 [17294131.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Jul;293(1):C12-21 [17475665.001]
  • [Cites] Gut. 2007 Aug;56(8):1134-52 [17625148.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Dec 7;364(1):131-7 [17931597.001]
  • [Cites] Clin Cancer Res. 2009 Mar 1;15(5):1593-600 [19223492.001]
  • [Cites] BMC Cancer. 2009;9:327 [19754967.001]
  • [Cites] Oral Oncol. 2001 Jan;37(1):72-6 [11120486.001]
  • (PMID = 20202214.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2841142
  •  go-up   go-down


2. Ohtsubo K, Watanabe H, Yamada T, Tsuchiyama T, Mouri H, Yamashita K, Yasumoto K, Ikeda H, Nakanuma Y, Yano S: Cancer of unknown primary site in which tumor marker-oriented chemotherapy was effective and pancreatic cancer was finally confirmed at autopsy. Intern Med; 2009;48(18):1651-6
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer of unknown primary site in which tumor marker-oriented chemotherapy was effective and pancreatic cancer was finally confirmed at autopsy.
  • We report a 47-year-old man with cancer of unknown primary site in whom pancreatic cancer was confirmed at autopsy.
  • Although a primary lesion was not confirmed, we planned to perform tumor marker-oriented chemotherapy because pancreatic cancer was suspected as the primary lesion based on tumor markers and pathological findings from metastatic lymph node.
  • However, gemcitabine combined with low-dose cisplatin therapy resulted in a marked decrease in the size of tumors.
  • Microscopic examination at autopsy revealed poorly differentiated adenocarcinoma in the pancreatic head, although a pancreatic mass was not clear macroscopically.
  • [MeSH-major] Neoplasms, Unknown Primary / diagnosis. Neoplasms, Unknown Primary / drug therapy. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / drug therapy. Adenocarcinoma / metabolism. Adenocarcinoma / secondary. Antigens, Neoplasm / metabolism. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Autopsy. Biomarkers, Tumor / metabolism. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Humans. Lung Neoplasms / diagnosis. Lung Neoplasms / drug therapy. Lung Neoplasms / metabolism. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19755768.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / DU-PAN-2 antigen, human; 0 / pancreatic associated antigen, SPan-1; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


3. Terashima T, Matsuzaki T, Kawada I, Nishida J, Tanaka Y, Morishita T, Takeyasu Y, Yamane GY, Uchiyama T: Tongue metastasis as an initial presentation of a lung cancer. Intern Med; 2004 Aug;43(8):727-30
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tongue metastasis as an initial presentation of a lung cancer.
  • Metastasis to the tongue seldom occurs, and lingual metastasis as an initial sign of cancer occurs even less frequently.
  • We report a case of lung cancer in which the patient's initial symptom was related to the tongue metastasis.
  • A 63-year-old man had a submucosal tumor on the left posterolateral aspect of the tongue and a biopsy specimen of the tongue tumor showed poorly differentiated squamous cell carcinoma.
  • A chest X-ray showed a mass in the right lung and cytological examination of the specimen obtained by bronchial brushing showed poorly differentiated squamous cell carcinoma, whose appearance was similar to that of the tongue.
  • Based on these findings, the tongue lesion was diagnosed a metastatic tumor from the lung cancer.
  • The patient received radiation therapy combined with systemic chemotherapy, however, he died 5 months after the diagnosis of lung cancer.
  • An autopsy revealed a lung cancer in the right lower lobe with metastatic tumors in the tongue, right middle lobe, left upper lobe, liver, adrenal gland, pericardium, heart, and subcutaneous tissues.
  • No other possible primary cancer that may have been the cause of the metastases was identified.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Lung Neoplasms / pathology. Tongue Neoplasms / secondary
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Fatal Outcome. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Tongue cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15468975.001).
  • [ISSN] 0918-2918
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


Advertisement
4. Nabeshima S, Kishihara Y, Nabeshima A, Yamaga S, Kinjo M, Kashiwagi S, Hayashi J: Poorly differentiated adenocarcinoma with signet-ring cells of the Vater's ampulla, without jaundice but with disseminated carcinomatosis. Fukuoka Igaku Zasshi; 2003 Jul;94(7):235-40
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poorly differentiated adenocarcinoma with signet-ring cells of the Vater's ampulla, without jaundice but with disseminated carcinomatosis.
  • To reduce tumor cells in number and improve DIC, 11 cycles of 5-Fluorouracil and leucovorin therapy were done, and the patient survived for 12 months.
  • Autopsy showed a 0.8 cm diameter, poorly differentiated adenocarcinoma with the signet-ring cell type in the lamina propria of the Vater's ampulla.
  • Many metastatic foci and micro tumor emboli were found in the lung and in bone marrow.
  • These findings suggest that the origin of the cancer may have been located in the Vater's ampulla.
  • This is a rare case of an ampullary tumor of poorly differentiated adenocarcinoma with the signet-ring cell type, without jaundice but with multiple metastasis.
  • 5-Fluorouracil and leucovorin were effective for increasing survival time and improving quality of life.
  • [MeSH-major] Ampulla of Vater. Bone Marrow Neoplasms / secondary. Carcinoma, Signet Ring Cell / pathology. Common Bile Duct Neoplasms / pathology. Lung Neoplasms / secondary
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disseminated Intravascular Coagulation / complications. Disseminated Intravascular Coagulation / drug therapy. Fatal Outcome. Fluorouracil / administration & dosage. Humans. Jaundice. Leucovorin / administration & dosage. Male. Middle Aged. Neoplastic Cells, Circulating / pathology. Quality of Life

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14509231.001).
  • [ISSN] 0016-254X
  • [Journal-full-title] Fukuoka igaku zasshi = Hukuoka acta medica
  • [ISO-abbreviation] Fukuoka Igaku Zasshi
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


5. Hainsworth JD, Spigel DR, Litchy S, Greco FA: Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study. J Clin Oncol; 2006 Aug 1;24(22):3548-54
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study.
  • PURPOSE: To evaluate the efficacy of chemotherapy with paclitaxel, carboplatin, and etoposide in advanced adult poorly differentiated neuroendocrine carcinomas.
  • PATIENTS AND METHODS: Patients eligible for this multicenter, phase II trial had metastatic poorly differentiated neuroendocrine carcinoma and had received no previous treatment.
  • Patients with a variety of known primary sites (excepting small-cell lung cancer) and patients with unknown primary site were eligible.
  • Patients received four courses of chemotherapy with paclitaxel, carboplatin, and etoposide, administered at 3-week intervals.
  • After completing four courses of treatment, patients with objective response or stable disease received three courses (24 weeks) of weekly paclitaxel.
  • Forty-one patients (53%) had major responses (complete response rate, 15%), and five patients remain disease free from 18 to 66 months after therapy.
  • Response rates were similar regardless of histology (small-cell v poorly differentiated carcinoma) or primary site.
  • CONCLUSION: This prospective phase II trial provides additional evidence that this family of relatively uncommon carcinomas is initially chemosensitive, with a high overall response rate to combination chemotherapy and a minority of complete responses.
  • The three-drug regimen evaluated in this trial is moderately toxic, and has no obvious efficacy advantages when compared with standard platinum/etoposide regimens.
  • Treatment for advanced poorly differentiated neuroendocrine carcinoma should parallel treatments used for small-cell lung cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Neuroendocrine / drug therapy. Carcinoma, Neuroendocrine / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carboplatin / administration & dosage. Disease-Free Survival. Drug Administration Schedule. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Prospective Studies. Survival Analysis. Treatment Outcome

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16877720.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


6. Chivukula M, Dincer HE, Biller JA, Krouwer HG, Simon G, Shidham V: FNAB cytology of extra-cranial metastasis of glioblastoma multiforme may resemble a lung primary: a diagnostic pitfall. Cytojournal; 2005 Jun 20;2:9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FNAB cytology of extra-cranial metastasis of glioblastoma multiforme may resemble a lung primary: a diagnostic pitfall.
  • CASE PRESENTATION: We present transbronchial FNAB findings in a 62-year-old smoker with lung mass clinically suspicious for a lung primary.
  • The smears of transbronchial FNAB showed groups of cells with ill-defined cell margins and cytological features overlapping with poorly differentiated non-small cell carcinoma.
  • Further scrutiny of clinical details revealed a history of GBM, 13 months status-post surgical excision with radiation therapy and systemic chemotherapy.
  • The tumor recurred 7 months earlier and was debulked surgically and with intra-cranial chemotherapy.
  • Additional evaluation of tumor cells for glial fibrillary acidic protein (GFAP) immunoreactivity with clinical details resulted in final interpretation of metastatic GBM.
  • CONCLUSION: Lack of clinical history and immunophenotyping may lead to a diagnostic pitfall with possible misinterpretation of metastatic GBM as poorly differentiated non-small cell carcinoma of lung in a smoker.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Acad Dermatol. 2002 Feb;46(2):297-300 [11807444.001]
  • [Cites] Lung Cancer. 1998 May;20(2):135-7 [9711532.001]
  • [Cites] Cytopathology. 1997 Dec;8(6):421-7 [9439895.001]
  • [Cites] Diagn Cytopathol. 2004 Feb;30(2):77-81 [14755755.001]
  • (PMID = 15967023.001).
  • [ISSN] 1742-6413
  • [Journal-full-title] CytoJournal
  • [ISO-abbreviation] Cytojournal
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1183264
  •  go-up   go-down


7. Afchain P, Chibaudel B, Lledo G, Selle F, Bengrine-Lefevre L, Nguyen S, Paitel JF, Mineur L, Artru P, André T, Louvet C: First-line simplified GEMOX (S-GemOx) versus classical GEMOX in metastatic pancreatic cancer (MPA): results of a GERCOR randomized phase II study. Bull Cancer; 2009 May;96(5):E18-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] First-line simplified GEMOX (S-GemOx) versus classical GEMOX in metastatic pancreatic cancer (MPA): results of a GERCOR randomized phase II study.
  • PATIENTS AND METHODS: Patients (pts) with MPA were 2:1 randomly assigned for first-line treatment to S-GemOx (gemcitabine 1,000 mg/m(2), 100-minute infusion D1 immediately followed by oxaliplatin 100 mg/m(2), 120-minute infusion) or to GemOx (Gem D1 and ox D2).
  • Treatment was repeated in each arm every 2 weeks until disease progression.
  • Populations were well balanced for age (64.9 vs 66.6 years); gender (57 vs 65% male), location of primary tumor (pancreas head: 49 vs 50%), and metastatic sites (liver 76 vs 85%; peritoneum 24 vs 20%; lung 16 vs 10%; lymph nodes 14 vs 15%; other 5 vs 5%).
  • Tumor differentiation significantly differed between the 2 groups (S-GemOx: 8% poorly differentiated vs GemOx: 36%).
  • CONCLUSIONS: Activity and tolerance of S-GemOx are in the same range as compared to our previous experiences of classical GemOx in metastatic pancreatic cancer.
  • The very bad outcome of patients randomized in GemOx arm could at least be in part explained by the high-rate of poorly differentiated tumors.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Organoplatinum Compounds / administration & dosage. Organoplatinum Compounds / adverse effects. Remission Induction


8. Sun W, Powell M, O'Dwyer PJ, Catalano P, Ansari RH, Benson AB 3rd: Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol; 2010 Jun 20;28(18):2947-51
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203.
  • PURPOSE: The combination of sorafenib with chemotherapy is well-tolerated and is associated with encouraging response rates in several malignances.
  • Both docetaxel and cisplatin are active in gastric cancer.
  • A phase II study was conducted to determine the efficacy and toxicity of combined sorafenib, docetaxel, and cisplatin in patients with metastatic or advanced adenocarcinoma of stomach or gastroesophageal junction (GEJ).
  • PATIENTS AND METHODS: Forty-four chemotherapy-naïve patients with Eastern Cooperative Oncology Group performance status 0 or 1, of whom 80% had metastatic disease and two thirds had poorly differentiated gastric or GEJ adenocarcinoma, were enrolled.
  • The treatment regimen was sorafenib 400 mg orally twice a day for 21 days, docetaxel 75 mg/m(2) intravenously on day 1, and cisplatin 75 mg/m(2) intravenously on day 1, repeated every 21 days.
  • Additional studies of sorafenib with chemotherapy are warranted in gastric cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophagogastric Junction / drug effects. Esophagogastric Junction / pathology. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Benzenesulfonates / administration & dosage. Cisplatin / administration & dosage. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Niacinamide / analogs & derivatives. Phenylurea Compounds. Pyridines / administration & dosage. Survival Rate. Taxoids / administration & dosage. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):481-7 [12181402.001]
  • [Cites] Nat Rev Cancer. 2002 Oct;2(10):795-803 [12360282.001]
  • [Cites] J Clin Invest. 2003 May;111(9):1287-95 [12727920.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7099-109 [15466206.001]
  • [Cites] Br J Surg. 1998 Nov;85(11):1457-9 [9823902.001]
  • [Cites] Br J Cancer. 1999 Apr;80(1-2):269-72 [10390007.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):4991-7 [17075117.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):125-34 [17215530.001]
  • [Cites] Eur J Cancer. 2007 Jan;43(1):55-63 [17095207.001]
  • [Cites] Clin Lung Cancer. 2007 May;8(6):396-8 [17562243.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3217-23 [17664469.001]
  • [Cites] N Engl J Med. 2008 Jan 3;358(1):36-46 [18172173.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):378-90 [18650514.001]
  • [Cites] Clin Cancer Res. 2008 Aug 1;14(15):4836-42 [18676756.001]
  • [Cites] Mol Cancer Ther. 2008 Oct;7(10):3129-40 [18852116.001]
  • [Cites] J Clin Oncol. 2009 Mar 10;27(8):1280-9 [19171708.001]
  • [Cites] Ann Oncol. 2009 Apr;20(4):666-73 [19153121.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] J Clin Oncol. 2009 Sep 10;27(26):4274-80 [19652055.001]
  • [CommentIn] J Clin Oncol. 2010 Jun 20;28(18):2937-8 [20458025.001]
  • (PMID = 20458043.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA66636; United States / NCI NIH HHS / CA / U10 CA021115; United States / NCI NIH HHS / CA / U10 CA017145; United States / NCRR NIH HHS / RR / UL1 RR025741; United States / NCI NIH HHS / CA / U10 CA066636; United States / NCI NIH HHS / CA / CA17145; United States / NCI NIH HHS / CA / U10 CA023318; United States / NCI NIH HHS / CA / CA15488; United States / NCI NIH HHS / CA / CA21115; United States / NCI NIH HHS / CA / CA23318; United States / NCI NIH HHS / CA / U10 CA015488
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 0 / Taxoids; 15H5577CQD / docetaxel; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC2903332
  •  go-up   go-down


9. Sella A, Konichezky M, Flex D, Sulkes A, Baniel J: Low PSA metastatic androgen- independent prostate cancer. Eur Urol; 2000 Sep;38(3):250-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low PSA metastatic androgen- independent prostate cancer.
  • OBJECTIVES: To describe the clinical parameters of low PSA, progressive metastatic androgen-independent prostate cancer.
  • METHODS: From April 1995 to May 1999, we selected 18 patients with clinically progressive androgen-independent prostate cancer and low PSA (</=10 ng/ml).
  • Patients received cisplatin-based therapy.
  • Metastases involved bone in 11 patients (61.1%) - 5 (27.7%) blastic, 2 (11.1%) lytic, and 4 (22.2%) combined - liver in 10 patients (55.5%), lymph nodes in 8 (44.4%), and lung in 6 (33.3%); solitary sites as orbit, skin and spleen were noted as well.
  • Of the 12 patients who consented to chemotherapy, 8 (66.6%) achieved an objective response (95% CI, 34.
  • Hematoxylin and eosin evaluation revealed two major groups: neuroendocrine tumors, either pure small cell cancer in 6 patients (37.5%) or combined small cell cancer and adenocarcinoma in 8 (50%), and predominant poorly differentiated prostate cancer in 2 (12.5%).
  • CONCLUSIONS: Progressive androgen-independent prostate cancer with low serum PSA is characterized by visceral metastases, high proportion of lytic bone disease, sensitivity to cisplatin-based chemotherapy, and histological features of small cell or poorly differentiated prostate cancer.
  • In this subgroup of patients, selection of the therapeutic approach can be based on clinical parameters.


10. Ye M, Wang L, Fu X: [Accelerated hyperfractionation radiation therapy combined with chemotherapy for non-small cell lung cancer complicated with superior vena cava syndrome]. Zhonghua Zhong Liu Za Zhi; 2001 Sep;23(5):426-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Accelerated hyperfractionation radiation therapy combined with chemotherapy for non-small cell lung cancer complicated with superior vena cava syndrome].
  • OBJECTIVE: This retrospective study was done to evaluate the patient's tolerance and effect of accelerated hyperfractionation radiation therapy in the treatment of superior vena cava syndrome (SVCS) caused by non-small cell lung cancer (NSCLC).
  • According to their pathological diagnosis, there were 17(50%) squamous cell carcinomas, 14(41.2%) adenocarcinomas, 2(5.9%) mixed squamous and adenocarcinomas and 1(2.96%) poorly differentiated carcinomas.
  • For these patients, chemotherapy IEP or IAP (IFO 2.0 g d1-4, DDP 40 mg d1-3, Vp-16 0.1 g d1-3 or ADM 50 mg d1) was given first.
  • Twenty-four to 72 hours after chemotherapy, accelerated hyperfractionation radiation therapy was started to deliver to the primary tumor and the metastatic mediastinal lymph nodes, a tumor dose of 30 Gy/20 fx/2 wk followed by a boost to 36-40.8 Gy/30-34 fx/3-3.5 wk.
  • Diuretics, steroids and dehydrating agents were concomittantly prescribed during the radiation therapy.
  • Radiation therapy combined with chemotherapy gives similar results as non-surgery for stage III NSCLC.
  • No significant difference in the survival rates of the various histological types is observed.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / radiotherapy. Lung Neoplasms / radiotherapy. Superior Vena Cava Syndrome / radiotherapy
  • [MeSH-minor] Adenocarcinoma / complications. Adenocarcinoma / drug therapy. Adenocarcinoma / physiopathology. Adenocarcinoma / radiotherapy. Adult. Aged. Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / physiopathology. Carcinoma, Squamous Cell / radiotherapy. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Radiation Dosage. Retrospective Studies. Survival Rate. Treatment Outcome


11. Salama AR, Jham BC, Papadimitriou JC, Scheper MA: Metastatic neuroendocrine carcinomas to the head and neck: report of 4 cases and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2009 Aug;108(2):242-7
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic neuroendocrine carcinomas to the head and neck: report of 4 cases and review of the literature.
  • Neuroendocrine carcinoma (NEC) is a cancer arising from neuroendocrine cells, most commonly in the lungs.
  • Here, we present 4 cases of metastatic NEC to the jaws and major salivary glands.
  • Three primaries were located in the lung and one in the breast.
  • Histologic and immunohistochemical examination revealed 2 well-differentiated NEC and 2 poorly differentiated NEC.
  • Treatment included surgery, radiation, and chemotherapy.
  • [MeSH-minor] Aged. Aged, 80 and over. Breast Neoplasms / pathology. Breast Neoplasms / therapy. Female. Humans. Lung Neoplasms / pathology. Lung Neoplasms / therapy. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19615663.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 23
  •  go-up   go-down


12. Kulke MH, Wu B, Ryan DP, Enzinger PC, Zhu AX, Clark JW, Earle CC, Michelini A, Fuchs CS: A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors. Dig Dis Sci; 2006 Jun;51(6):1033-8
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors.
  • The role of systemic chemotherapy in the treatment of patients with metastatic neuroendocrine tumors is controversial.
  • While combination regimens containing cisplatin and etoposide have activity against more aggressive neuroendocrine tumor variants, such regimens appear to have little efficacy in patients with well-differentiated neuroendocrine tumor subtypes.
  • The combination of irinotecan and cisplatin is active both against small cell lung cancer and in upper gastrointestinal malignancies but has not been prospectively evaluated in patients with metastatic neuroendocrine tumors.
  • Eighteen patients with metastatic neuroendocrine tumors (excluding small cell carcinoma) were treated with irinotecan, 65 mg/m2, and cisplatin, 30 mg/m2, administered weekly for 2 of every 3 weeks.
  • Only one radiologic response was observed among four patients with poorly differentiated neuroendocrine tumors.
  • No radiologic responses were observed in 14 patients with well-differentiated tumors.
  • We conclude that while the combination of irinotecan and cisplatin may have activity in aggressive neuroendocrine tumor subtypes, this combination is inactive in patients with well-differentiated neuroendocrine tumors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Cisplatin / administration & dosage. Digestive System Neoplasms / drug therapy. Neuroendocrine Tumors / drug therapy
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Female. Humans. Male. Massachusetts. Middle Aged. Neoplasm Metastasis. Survival Analysis. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 1995;425(6):547-60 [7697211.001]
  • [Cites] Cancer. 1996 Jan 15;77(2):402-8 [8625251.001]
  • [Cites] Cancer. 2001 Apr 15;91(8):1543-8 [11301403.001]
  • [Cites] Cancer. 2004 Sep 1;101(5):934-9 [15329900.001]
  • [Cites] N Engl J Med. 1992 Feb 20;326(8):519-23 [1310159.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):1068-74 [9508192.001]
  • [Cites] Am J Clin Oncol. 2004 Oct;27(5):485-8 [15596916.001]
  • [Cites] J Clin Oncol. 1984 Nov;2(11):1255-9 [6238136.001]
  • [Cites] Lancet. 1998 Oct 31;352(9138):1413-8 [9807987.001]
  • [Cites] Cancer. 2001 Sep 1;92(5):1101-7 [11571721.001]
  • [Cites] Ann Oncol. 2001 Aug;12(8):1139-43 [11583197.001]
  • [Cites] N Engl J Med. 2002 Jan 10;346(2):85-91 [11784874.001]
  • [Cites] N Engl J Med. 2000 Sep 28;343 (13):905-14 [11006366.001]
  • [Cites] Cancer. 1991 Jul 15;68(2):227-32 [1712661.001]
  • [Cites] Cancer. 1994 Mar 1;73(5):1505-8 [8111718.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12 ):3858-65 [9850031.001]
  • [Cites] J Clin Oncol. 2004 Dec 1;22(23):4762-71 [15570077.001]
  • [Cites] Cancer Clin Trials. 1979 Winter;2(4):327-34 [93982.001]
  • [Cites] Cancer. 1999 Sep 15;86(6):944-8 [10491519.001]
  • [Cites] Cancer Invest. 2004;22(3):353-9 [15493355.001]
  • [Cites] J Clin Oncol. 1999 Oct;17 (10 ):3270-5 [10506629.001]
  • (PMID = 16865563.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K23 CA 093401; United States / NHLBI NIH HHS / HL / K30 HL04095
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0H43101T0J / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


13. Huang YW, Yang JC, Chang YL, Tsang YM, Wang TH: Acute pancreatitis combined with acute Budd-Chiari syndrome as the initial manifestation of small cell lung cancer. J Formos Med Assoc; 2005 Jun;104(6):431-5
MedlinePlus Health Information. consumer health - Pancreatitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute pancreatitis combined with acute Budd-Chiari syndrome as the initial manifestation of small cell lung cancer.
  • Autopsy series have reported a 24-40% of pancreatic involvement in small cell lung cancer.
  • Budd-Chiari syndrome complicating lung cancer is a rarely reported condition.
  • We report a 68-year-old woman with extensive small cell lung cancer with the unusual initial presentation of both acute pancreatitis and acute Budd-Chiari syndrome.
  • Severe epigastralgia with radiation to back and progressive jaundice developed 2 days prior to admission.
  • Chest roentgenogram showed a mass lesion over the left lower lung field.
  • Poorly differentiated carcinoma cells were found in ascites and bone marrow.
  • The patient died on the ninth day of hospitalization before chemotherapy was initiated.
  • Prompt diagnosis of extensive-stage small cell lung cancer may allow early chemotherapy treatment which favorably influences recovery when the pancreatitis is mild.
  • Although prolonged survival might have been expected had this patient recovered from pancreatitis and received chemotherapy, diagnosis was delayed due to difficulty in immunohistochemical diagnosis of the tumor and the unusual clinical presentation.
  • The use of stains employing antibodies against neurofilament and neuron-specific enolase cell antigens is important for early diagnosis of poorly differentiated metastatic tumor cells.


14. Luttgen MS, Marrinucci D, Lazar D, Malchiodi M, Clark P, Huynh E, Bethel K, Bazhenova L, Nieva J, Kuhn P: Circulating tumor cells monitored over time in lung cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):11025

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating tumor cells monitored over time in lung cancer patients.
  • : 11025 Background: Circulating tumor cell (CTC) detection and enumeration is a valuable tool for monitoring cancer patient status and outcome.
  • While many current techniques employ immunomagnetic-enrichment based protocols focused on the importance of a particular CTC number as the indicator of patient status or outcome, we employ a cytometric, enrichment free approach using an immunofluorescent protocol to monitor CTC counts in patients with non-small cell lung cancer (NSCLC) over the course of treatment.
  • The histological subtypes in the 42 cases for which the data was available included adenocarcinoma (22/42), squamous cell carcinoma (6/42), large cell undifferentiated carcinoma (3/42), and non-small cell lung carcinoma not further described, poorly differentiated, or with a mixed pattern (11/42).
  • Patient response to therapy was determined by RECIST every 3 months between time 0 and time 12 mo.
  • 13 of 52 patients have CTC data for time 0 and 3 wks.
  • Only 4 of these patients (30.8%) show a correlation linking CTC count change between time 0 and 3 wks and clinical assessment.
  • 13 patients have CTC data for time 0 and 3 mo, 10 of whom show a correlation linking CTC count change between time 0 and 3 mo and clinical assessment.
  • 7 of the 8 patients (87.5%) showing stable or partial response at 3 mo show a decrease in CTC count between time 0 and 3 mo.
  • Five of the 6 patients (83.3%) clinically showing progressive disease at the 3 mo time point show an increase in CTC count between time 0 and 3 mo.
  • The patients that do not show a correlation linking CTC count change between time 0 and 3 mo and clinical assessment at 3 mo show a correlation at the 6 mo time point.
  • CONCLUSIONS: CTCs can be effectively enumerated in metastatic NSCLC patients, with the majority demonstrating CTCs in the setting of progressive disease.
  • The change in CTC count at 3 mo, but not at 3 wks, correlates with radiographic response to chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963968.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Miyahara H, Itou H, Sekine A, Taniyama D, Katsui T, Tanaka W, Satou R, Kurihara A, Satou Y, Sakamaki F: [A case of adult T-cell leukemia/lymphoma with primary lung cancer]. Nihon Kokyuki Gakkai Zasshi; 2009 Apr;47(4):342-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of adult T-cell leukemia/lymphoma with primary lung cancer].
  • Cranial MRI showed an enlarged mass 5cm in diameter with intracranial invasion and metastatic brain tumors.
  • The mass was pathologically diagnosed as adult T-cell leukemia/lymphoma (ATLL) because of a high HTLV-1 antibody titer, and radiation therapy was started.
  • Furthermore, since we noted multiple cervical lymphadenopathy, we performed an additional biopsy, which showed poorly-differentiated adenocarcinoma.
  • We diagnosed stage IV primary lung cancer and started chemotherapy.
  • However, he developed dyspnea due to pleural effusion and his performance status gradually decreased to 3.
  • Autopsy showed ATLL and extensive lung cancer with multiple metastases.
  • CONCLUSION: We encountered a rare case of ATLL and primary lung cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Leukemia-Lymphoma, Adult T-Cell / pathology. Lung Neoplasms / pathology. Neoplasms, Multiple Primary

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19455967.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


16. Nguyen NC, Sayed MM, Taalab K, Osman MM: Spinal cord metastases from lung cancer: detection with F-18 FDG PET/CT. Clin Nucl Med; 2008 May;33(5):356-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal cord metastases from lung cancer: detection with F-18 FDG PET/CT.
  • Preoperative F-18 FDG PET/CT study in this 57-year-old woman showed an FDG avid lesion in the left upper lung without evidence of lymphadenopathy or distant metastasis.
  • She underwent a left upper lobectomy in June 2005 revealing moderately poorly differentiated adenocarcinoma (pT3N0M0) and subsequent chemotherapy completed December 2005.
  • Nine months later, a left parietal lobe metastatic lesion was surgically resected.
  • Clinically, the patient recently developed back pain without evidence of neurologic deficits.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / diagnosis. Carcinoma, Non-Small-Cell Lung / secondary. Fluorodeoxyglucose F18. Lung Neoplasms / diagnosis. Spinal Cord Neoplasms / diagnosis. Spinal Cord Neoplasms / secondary
  • [MeSH-minor] Female. Humans. Lumbar Vertebrae / radiography. Lumbar Vertebrae / radionuclide imaging. Positron-Emission Tomography / methods. Radiopharmaceuticals. Thoracic Vertebrae / radiography. Thoracic Vertebrae / radionuclide imaging. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18431157.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


17. Ramalingam P, Middleton LP, Tamboli P, Troncoso P, Silva EG, Ayala AG: Invasive micropapillary carcinoma of the breast metastatic to the urinary bladder and endometrium: diagnostic pitfalls and review of the literature of tumors with micropapillary features. Ann Diagn Pathol; 2003 Apr;7(2):112-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive micropapillary carcinoma of the breast metastatic to the urinary bladder and endometrium: diagnostic pitfalls and review of the literature of tumors with micropapillary features.
  • Carcinomas with micropapillary features have been described in the breast, urinary bladder, lung, and ovary.
  • The metastatic carcinoma can consist exclusively of the micropapillary component, which may elicit an erroneous diagnosis if located in the bladder or lung, as in the patient presented herein.
  • We present a case of a 59-year-old woman with a history of bilateral breast carcinoma status post-bilateral mastectomy, chemotherapy, and tamoxifen therapy.
  • A biopsy of the endometrium revealed a poorly differentiated carcinoma.
  • Anderson Cancer Center (Houston, TX) for further treatment recommendations.
  • In view of the morphologic and immunohistochemical profile, the carcinoma in the endometrium and urinary bladder were interpreted as metastatic lesions from the breast primary.
  • Carcinomas with a micropapillary component are morphologically identical in the breast, urinary bladder, and lung.
  • Immunohistochemical stains are useful in distinguishing these lesions in that thyroid transcription factor-1 positivity suggests a lung primary, CK7 and estrogen receptor suggest a breast primary, and both CK7 and CK20 positivity suggest a urinary bladder primary.
  • It is important to exclude metastatic carcinomas with micropapillary features before making a definite diagnosis of a primary tumor.
  • [MeSH-minor] Carcinoma, Transitional Cell / pathology. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Keratin-7. Keratins / metabolism. Lung Neoplasms / metabolism. Middle Aged. Receptors, Estrogen / metabolism

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Elsevier Inc. All rights reserved.
  • (PMID = 12715337.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / KRT7 protein, human; 0 / Keratin-7; 0 / Receptors, Estrogen; 68238-35-7 / Keratins
  •  go-up   go-down


18. Mego M, Sycova-Mila Z, Martanovic P, Liskova S, Obertova J, Mardiak J: Inflammatory skin metastasis as a first sign of progression of lung cancer--a case report. Klin Onkol; 2010;23(6):449-51
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory skin metastasis as a first sign of progression of lung cancer--a case report.
  • BACKGROUND: Skin metastases are present in 1-9% of cancer patients.
  • ICM in lung cancer are extremely rare and often misdiagnosed.
  • PATIENTS AND METHODS: We report on a 55-year-old man with metastatic lung adenocarcinoma and bone metastases in the axial skeleton and left humerus diagnosed in August 2008.
  • He underwent 6 cycles of palliative chemotherapy with cisplatin and gemcitabine, obtaining a minor response.
  • Five months later, he experienced increasing pain in his left arm, with erythematous oedematous lesion with poorly defined margins and an inflammatory appearance.
  • A diagnosis of skin infection was made and he was treated by antibiotic therapy without improvement.
  • RESULTS: Skin biopsy revealed skin infiltration by poorly differentiated carcinoma compatible with a primary lung tumour.
  • He was started on second line therapy with docetaxel, however, the patient's status deteriorated rapidly and he died two months after the first appearance of ICM.
  • CONCLUSION: Metastasis of lung carcinoma could be one of the causes of inflammatory skin lesions in cancer patients and these metastases should be considered in cancer patients with persisting cutaneous lesions with signs of inflammation and no response to antibiotic therapy.
  • [MeSH-major] Adenocarcinoma / secondary. Lung Neoplasms / pathology. Skin Neoplasms / secondary

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21348413.001).
  • [ISSN] 0862-495X
  • [Journal-full-title] Klinická onkologie : casopis Ceské a Slovenské onkologické spolecnosti
  • [ISO-abbreviation] Klin Onkol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


19. Irshad K, Ahmad F, Morin JE, Mulder DS: Pulmonary metastases from colorectal cancer: 25 years of experience. Can J Surg; 2001 Jun;44(3):217-21
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary metastases from colorectal cancer: 25 years of experience.
  • PATIENTS: Forty-nine patients treated surgically between 1975 and 1998 for pulmonary metastases from colorectal cancer.
  • Significant preoperative variables that carried a poor prognosis included the following: more than one pulmonary lesion, a disease-free interval of less than 2 years, and moderately or poorly differentiated colorectal cancer.
  • The 16 patients who received chemotherapy after their thoracotomy had a 5-year survival rate of 51% compared with 54% for the 33 patients who did not receive chemotherapy.
  • CONCLUSIONS: Pulmonary resection for metastatic colorectal cancer is both effective and safe.
  • Resectable extrapulmonary metastases and pulmonary recurrence should not preclude lung resection.
  • Postoperative chemotherapy has no survival benefit.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Colorectal Neoplasms / pathology. Lung Neoplasms / secondary. Lung Neoplasms / surgery

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11407833.001).
  • [ISSN] 0008-428X
  • [Journal-full-title] Canadian journal of surgery. Journal canadien de chirurgie
  • [ISO-abbreviation] Can J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC3699122
  •  go-up   go-down


20. Hirasaki S, Suzuki S, Umemura S, Kamei H, Okuda M, Kudo K: Asymptomatic colonic metastases from primary squamous cell carcinoma of the lung with a positive fecal occult blood test. World J Gastroenterol; 2008 Sep 21;14(35):5481-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Asymptomatic colonic metastases from primary squamous cell carcinoma of the lung with a positive fecal occult blood test.
  • We describe a 74-year-old man with a colonic metastatic squamous cell carcinoma (SCC) from the lung.
  • Computed tomography (CT) of the chest demonstrated a large lung tumor in the right upper lobe obstructing the right upper bronchus.
  • Bronchoscopy revealed an easy-bleeding tumor in the right upper bronchus that was diagnosed as poorly differentiated squamous cell lung carcinoma.
  • The lesion was diagnosed as metastatic colonic SCC.
  • He underwent chemotherapy with an infusion of cisplatin 130 mg i.v. day 1, and docetaxel hydrate 100 mg i.v. day 1, repeated every 4 wk, followed by 4 courses of chemotherapy.
  • The primary lesion shrank by less than 10% and was judged to be "Partial Response" (PR) after 3 courses of treatment.
  • The patient still lived 23 wk after the diagnosis of metastatic colonic SCC.
  • Colonic metastasis of primary SCC of the lung is rare.
  • [MeSH-major] Carcinoma, Small Cell / secondary. Colonic Neoplasms / secondary. Lung Neoplasms

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 1980 Dec;74(6):504-6 [6259933.001]
  • [Cites] J Postgrad Med. 2002 Jul-Sep;48(3):199-200 [12432195.001]
  • [Cites] Cancer. 1987 Apr 15;59(8):1486-9 [3028602.001]
  • [Cites] J Surg Oncol. 1992 Dec;51(4):287-91 [1434663.001]
  • [Cites] Br J Clin Pract. 1993 Sep-Oct;47(5):276-7 [8292483.001]
  • [Cites] Nihon Kyobu Shikkan Gakkai Zasshi. 1996 Sep;34(9):968-72 [8937139.001]
  • [Cites] Tuberk Toraks. 2005;53(3):280-3 [16258889.001]
  • [Cites] Kyobu Geka. 2006 May;59(5):426-9 [16715897.001]
  • [Cites] J Clin Oncol. 2006 Oct 20;24(30):4939-40 [17050879.001]
  • [Cites] Lung Cancer. 2006 Dec;54(3):319-23 [17010474.001]
  • [Cites] J Thorac Oncol. 2007 Feb;2(2):115-20 [17410025.001]
  • [Cites] J Cancer Res Clin Oncol. 2009 Feb;135(2):297-301 [18512073.001]
  • [Cites] Eur J Cardiothorac Surg. 2001 May;19(5):719-20 [11343961.001]
  • [Cites] Acta Chir Belg. 2001 Nov-Dec;101(6):300-3 [11868507.001]
  • [Cites] Cancer. 1982 Jan 1;49(1):170-2 [6274500.001]
  • (PMID = 18803365.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2744902
  •  go-up   go-down


21. Pavlidis N, Briasoulis E, Hainsworth J, Greco FA: Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer; 2003 Sep;39(14):1990-2005
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic and therapeutic management of cancer of an unknown primary.
  • Metastatic Cancer of Unknown Primary Site (CUP) accounts for approximately 3% of all malignant neoplasms and is therefore one of the 10 most frequent cancer diagnoses in man.
  • Patients with CUP present with metastatic disease for which the site of origin cannot be identified at the time of diagnosis.
  • The following clinicopathological entities have been recognised: (i) metastatic CUP primarily to the liver or to multiple sites, (ii) metastatic CUP to lymph nodes including the sub-sets involving primarily the mediastinal-retroperitoneal, the axillary, the cervical or the inguinal nodes, (iii) metastatic CUP of peritoneal cavity including the peritoneal papillary serous carcinomatosis in females and the peritoneal non-papillary carcinomatosis in males or females, (iv) metastatic CUP to the lungs with parenchymal metastases or isolated malignant pleural effusion, (v) metastatic CUP to the bones, (vi) metastatic CUP to the brain, (vii) metastatic neuroendocrine carcinomas and (viii) metastatic melanoma of an unknown primary.
  • Extensive work-up with specific pathology investigations (immunohistochemistry, electron microscopy, molecular diagnosis) and modern imaging technology (computed tomography (CT), mammography, Positron Emission Tomography (PET) scan) have resulted in some improvements in diagnosis; however, the primary site remains unknown in most patients, even on autopsy.
  • The most frequently detected primaries are carcinomas hidden in the lung or pancreas.
  • Several favourable sub-sets of CUP have been identified, which are responsive to systemic chemotherapy and/or locoregional treatment.
  • Identification and treatment of these patients is of paramount importance.
  • The considered responsive sub-sets to platinum-based chemotherapy are the poorly differentiated carcinomas involving the mediastinal-retroperitoneal nodes, the peritoneal papillary serous adenocarcinomatosis in females and the poorly differentiated neuroendocrine carcinomas.
  • Other tumours successfully managed by locoregional treatment with surgery and/or irradiation are the metastatic adenocarcinoma of isolated axillary nodes, metastatic squamous cell carcinoma of cervical nodes, or any other single metastatic site.
  • Empirical chemotherapy benefits some of the patients who do not fit into any favourable sub-set, and should be considered in patients with a good performance status.
  • [MeSH-major] Neoplasms, Unknown Primary / diagnosis. Neoplasms, Unknown Primary / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Cancer. 2004 Jun;40(9):1454-5 [15177507.001]
  • (PMID = 12957453.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 119
  •  go-up   go-down


22. Cormio G, Colamaria A, Di Vagno G, De Tommasi A, Loverro G, Selvaggi L: Surgical decompression and radiation therapy in epidural metastasis from cervical cancer. Eur J Obstet Gynecol Reprod Biol; 2000 Mar;89(1):59-61
MedlinePlus Health Information. consumer health - Cervical Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical decompression and radiation therapy in epidural metastasis from cervical cancer.
  • We report three patients treated for a cervical carcinoma who developed epidural metastasis with spinal cord compression at 9, 25 and 48 months after primary treatment of the uterine malignancy.
  • All patients had poorly-differentiated adenocarcinomas with lymphovascular space invasion, and two had lymph node metastasis.
  • In two patients the spinal cord was the only site of recurrent disease, whereas the other had lung and brain metastasis at the time of epidural involvement diagnosis.
  • Surgical decompression followed by radiation therapy may result in a complete preservation of the neurologic functions in patients with spinal cord compression secondary to metastatic carcinoma of the uterine cervix.
  • Considering the propensity for disseminated disease, long term survival might be achieved only with the use of effective chemotherapy.
  • [MeSH-minor] Adenocarcinoma / complications. Adenocarcinoma / radiotherapy. Adenocarcinoma / secondary. Adult. Brain Neoplasms / secondary. Fatal Outcome. Female. Humans. Laminectomy. Lung Neoplasms / secondary. Lymphatic Metastasis. Middle Aged

  • Genetic Alliance. consumer health - Cervical cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10733025.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] IRELAND
  •  go-up   go-down


23. Miura T, Shimaoka Y, Nakamura J, Yamada S, Miura T, Yanagi M, Sato K, Usuda H, Emura I, Takahashi T: TTF-1 is useful for primary site determination in duodenal metastasis. World J Gastrointest Oncol; 2010 Sep 15;2(9):360-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report here on a case of duodenal metastasis from primary lung adenocarcinoma.
  • A 69-year old man was diagnosed with primary lung adenocarcinoma.
  • Four courses of combined chemotherapy with carboplatin and paclitaxel associated with irradiation of 60 Gy shrunk the lung tumor.
  • Differential diagnosis between malignant lymphoma and metastatic duodenal cancer was endoscopically difficult.
  • The histology of biopsied specimens was poorly differentiated adenocarcinoma.
  • Thus, we concluded that these were metastatic duodenal tumors from lung adenocarcinoma.
  • Two courses of gemcitabine led to a complete remission in this duodenal metastasis and para-aortic lymph node swelling with only scarring remaining in computed tomography.
  • He is now on the continuous generalized chemotherapy.
  • In conclusion, duodenal metastasis from primary lung adenocarcinoma is rare and hard to diagnose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21160807.001).
  • [ISSN] 1948-5204
  • [Journal-full-title] World journal of gastrointestinal oncology
  • [ISO-abbreviation] World J Gastrointest Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2999137
  • [Keywords] NOTNLM ; Duodenal metastasis / Lung adenocarcinoma / Thyroid transcription factor-1
  •  go-up   go-down


24. Latz C, Huang Q, Kapadia MK, Freitag SK: Metastasis to eyelid as initial presentation of non-small cell carcinoma. Ophthal Plast Reconstr Surg; 2009 Sep-Oct;25(5):406-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histopathology revealed a poorly differentiated carcinoma.
  • The patient underwent a systemic workup including CT of the lungs and was subsequently diagnosed with stage IV non-small cell carcinoma presumably of the lung.
  • He received palliative radiation and chemotherapy and died 5 months after initial presentation.
  • This report illustrates a case where metastatic eyelid disease was the presenting sign of hitherto undiagnosed lung cancer.
  • It is followed by a review of clinical aspects of metastatic eyelid disease.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / secondary. Eyelid Neoplasms / secondary. Lung Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Fatal Outcome. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19966662.001).
  • [ISSN] 1537-2677
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


25. Mitry E, Rougier P: The treatment of undifferentiated neuroendocrine tumors. Crit Rev Oncol Hematol; 2001 Jan;37(1):47-51

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The treatment of undifferentiated neuroendocrine tumors.
  • The aggressiveness of poorly-differentiated neuroendocrine tumors is similar to small-cell lung cancer within a median survival of 6 months without treatment.
  • Most patients have metastatic disease and poor condition at the time of diagnosis, and cannot be approached surgically with curative intent.
  • [Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin, Cancer 1991;68:227--232] reported an objective response rate of 67% with a chemotherapy regimen combining etoposide plus cisplatin, with a median survival of 19 months and a median time to progression of 11 months.
  • Since this publication, this regimen has been considered as the reference treatment for poorly-differentiated neuroendocrine tumors.
  • However, the prognosis remains poor with a 2-year survival lower than 20% and other therapeutic approaches should be developed.
  • [MeSH-major] Neuroendocrine Tumors / drug therapy. Neuroendocrine Tumors / pathology
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Neuroendocrine / drug therapy. Carcinoma, Neuroendocrine / mortality. Carcinoma, Neuroendocrine / pathology. Cell Differentiation / drug effects. Cell Differentiation / physiology. Female. Humans. Male. Middle Aged. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11164718.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 28
  •  go-up   go-down


26. Takeyama H, Takahashi H, Tabei I, Fukuchi O, Nogi H, Kinoshita S, Uchida K, Morikawa T: Malignant neoplasm in the axilla of a male: suspected primary carcinoma of an accessory mammary gland. Breast Cancer; 2010 Apr;17(2):151-4
MedlinePlus Health Information. consumer health - Male Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Incisional biopsy for suspected malignancy was performed, and histopathologic examination by hematoxylin-eosin (H&E) staining yielded a diagnosis of poorly differentiated adenocarcinoma metastatic from an unknown primary.
  • As the tumor was immunohistochemically positive for both ER and PgR, metastatic breast cancer was strongly suspected.
  • Detailed examination of the head and neck region, lung, and upper and lower gastrointestinal tract also revealed no evidence of a primary tumor.
  • After chemotherapy, the patient underwent tumor resection with axillary lymph node dissection.
  • On the basis of the histological features of H&E-stained specimens and immunohistochemistry of the resected tumor, this case was diagnosed as breast cancer of unknown origin in a male.
  • The tumor could have been an axillary lymph node metastasis from an occult breast carcinoma, or primary cancer arising in an accessory mammary gland.
  • [MeSH-minor] Axilla. Diagnosis, Differential. Humans. Lymphatic Metastasis. Male. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19387775.001).
  • [ISSN] 1880-4233
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


27. Greco FA, Erland JB, Morrissey LH, Burris HA 3rd, Hermann RC, Steis R, Thompson D, Gray J, Hainsworth JD: Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin. Ann Oncol; 2000 Feb;11(2):211-5
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To evaluate the toxicity, response rate and short-term survival associated with the chemotherapy combinations of docetaxel plus cisplatin or carboplatin when used for the treatment of patients with metastatic carcinoma of unknown primary site.
  • Stable or responding patients received a maximum of eight courses of therapy.
  • The majority of patients had two or more sites of metastasis; about 45% had adenocarcinoma and 50% poorly differentiated carcinoma.
  • RESULTS: In study A, 6 of 23 (26%) assessable patients had a major response to therapy.
  • In study B, 9 of 40 assessable patients (22%) had a major response to therapy.
  • Comparative phase III trials will be necessary to unequivically prove a survival advantage for any form of therapy in these patients.
  • However, the survival for patients with carcinoma of unknown primary site receiving docetaxel-based chemotherapy is comparable to the survivals for several other groups of advanced cancer patients, such as non-small cell lung cancer, receiving various types of chemotherapy.

  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10761758.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


28. Mikhaylova M, Stasinopoulos I, Kato Y, Artemov D, Bhujwalla ZM: Imaging of cationic multifunctional liposome-mediated delivery of COX-2 siRNA. Cancer Gene Ther; 2009 Mar;16(3):217-26
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Liposomes are a useful means of delivering molecular targeting agents such as small interfering RNA (siRNA) to downregulate specific pathways important in cancer growth and progression.
  • As cyclooxygenase-2 (COX-2) is an important therapeutic target in cancer, we investigated loading COX-2-specific siRNA into cationic liposomes containing MR contrast agents for imaging delivery in cancer cells and tumors.
  • These lipoplexes were used for cell transfection of the poorly differentiated and highly metastatic breast cancer cell line MDA-MB-231.
  • PEGylated liposomes loaded with Feridex and fluorescently labeled COX-2 siRNA were used for in vivo delivery of lipoplexes in MDA-MB-231 breast cancer xenografts in female SCID mice.
  • Biodistribution studies showed significant localization in the lung, liver and kidney at 24 h.
  • These data demonstrate the feasibility of liposomal-mediated delivery of COX-2-specific siRNA to downregulate COX-2 in cancer cells, and multi-modality imaging of the delivery of specific siRNA in tumors.

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Ferumoxides .
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cancer Ther. 2002 Mar;1(5):337-46 [12489850.001]
  • [Cites] Biosci Rep. 2002 Apr;22(2):129-50 [12428898.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Dec 26;312(4):1220-5 [14652004.001]
  • [Cites] Methods Mol Biol. 2004;252:515-22 [15017077.001]
  • [Cites] Gene Ther. 2004 Oct;11(19):1434-40 [15229629.001]
  • [Cites] J Natl Cancer Inst. 1974 Sep;53(3):661-74 [4412247.001]
  • [Cites] Cancer Res. 1986 Dec;46(12 Pt 1):6387-92 [2946403.001]
  • [Cites] FEBS Lett. 1987 Nov 16;224(1):104-8 [2890537.001]
  • [Cites] Biochim Biophys Acta. 1996 Jun 11;1281(2):139-49 [8664312.001]
  • [Cites] Pharm Res. 1996 Sep;13(9):1367-72 [8893276.001]
  • [Cites] Nature. 1997 May 1;387(6628):26-7 [9139818.001]
  • [Cites] Biochim Biophys Acta. 1998 Feb 16;1390(2):119-33 [9507083.001]
  • [Cites] Clin Cancer Res. 2004 Nov 15;10(22):7721-6 [15570006.001]
  • [Cites] Mol Ther. 2005 Oct;12(4):634-43 [16039164.001]
  • [Cites] Hum Gene Ther. 2006 Jan;17(1):117-24 [16409130.001]
  • [Cites] J Natl Cancer Inst. 2006 Jun 7;98(11):736-47 [16757698.001]
  • [Cites] Gene Ther. 2006 Aug;13(16):1222-34 [16625243.001]
  • [Cites] Nucleosides Nucleotides Nucleic Acids. 2006;25(8):889-907 [16901821.001]
  • [Cites] Mol Pharm. 2006 Sep-Oct;3(5):579-88 [17009857.001]
  • [Cites] Biomaterials. 2007 Mar;28(7):1434-42 [17141864.001]
  • [Cites] Int J Pharm. 2007 Mar 1;331(2):160-6 [17156952.001]
  • [Cites] Nat Med. 2007 Mar;13(3):372-7 [17322898.001]
  • [Cites] J Gene Med. 2007 Mar;9(3):170-83 [17351968.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):256-69 [17384581.001]
  • [Cites] Cell Cycle. 2007 Mar 15;6(6):682-5 [17374999.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):2938-43 [17409398.001]
  • [Cites] Mol Cancer Res. 2007 May;5(5):435-42 [17510310.001]
  • [Cites] Anticancer Agents Med Chem. 2006 May;6(3):221-32 [16712450.001]
  • [Cites] Drug Deliv. 2002 Jan-Mar;9(1):11-8 [11839204.001]
  • [Cites] Acad Radiol. 2002 Aug;9 Suppl 2:S484-7 [12188316.001]
  • [Cites] Nat Biotechnol. 2002 Oct;20(10):1006-10 [12244328.001]
  • [Cites] J Mol Biol. 2003 Apr 4;327(4):761-6 [12654261.001]
  • (PMID = 18927599.001).
  • [ISSN] 1476-5500
  • [Journal-full-title] Cancer gene therapy
  • [ISO-abbreviation] Cancer Gene Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA103175-05; United States / NCI NIH HHS / CA / 2R01 CA 82337; United States / NCI NIH HHS / CA / CA082337-10; United States / NCI NIH HHS / CA / CA091409-01; United States / NCI NIH HHS / CA / U54 CA091409; United States / NCI NIH HHS / CA / R01 CA082337-10; United States / NCI NIH HHS / CA / U54 CA091409-01; United States / NCI NIH HHS / CA / R01 CA082337; United States / NCI NIH HHS / CA / P50 CA103175; United States / NCI NIH HHS / CA / P50 CA103175-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cations; 0 / Contrast Media; 0 / Fluorescent Dyes; 0 / Liposomes; 0 / Magnetite Nanoparticles; 0 / Neoplasm Proteins; 0 / Organometallic Compounds; 0 / Oxides; 0 / RNA, Small Interfering; 30IQX730WE / Polyethylene Glycols; E1UOL152H7 / Iron; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; G6N3J05W84 / ferumoxides; I223NX31W9 / Fluorescein-5-isothiocyanate; K2I13DR72L / Gadolinium DTPA; K3R6ZDH4DU / Dextrans; XM0M87F357 / Ferrosoferric Oxide
  • [Other-IDs] NLM/ NIHMS276761; NLM/ PMC3052284
  •  go-up   go-down


29. Karnwal A, Hadjihannas E, Sherif A, Grumett S, Karnwal S, Mathews J: Amelanotic melanoma presenting with cervical lymphadenopathy. BMJ Case Rep; 2009;2009

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fine needle aspiration cytology of the mass suggested a poorly differentiated carcinoma.
  • Computed tomography showed a left sided, 8×13 cm cervical mass with liver, lung and bony metastases.
  • Histological examination of the lymph nodal mass confirmed the diagnosis of a metastatic amelanotic melanoma.
  • The patient was treated with glucocorticoids, radiation therapy for the sacral bony deposit, and chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Gynecol Obstet. 1963 Sep;117:341-5 [14080349.001]
  • [Cites] Melanoma Res. 2005 Feb;15(1):77-82 [15714125.001]
  • [Cites] Cancer. 2006 May 1;106(9):2012-20 [16568458.001]
  • [Cites] Otolaryngol Head Neck Surg. 1981 Jul-Aug;89(4):594-8 [6793970.001]
  • [Cites] Cancer. 1997 May 1;79(9):1816-21 [9129001.001]
  • [Cites] Clin Otolaryngol Allied Sci. 1994 Apr;19(2):161-5 [8026097.001]
  • (PMID = 21686931.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3028389
  •  go-up   go-down


30. Youn JC, Rhee Y, Park SY, Kim WH, Kim SJ, Chung HC, Hong SW, Lim SK: Severe hypothyroidism induced by thyroid metastasis of colon adenocarcinoma: a case report and review of the literature. Endocr J; 2006 Jun;53(3):339-43
Hazardous Substances Data Bank. LEVOTHYROXINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An 85-year-old man who had undergone a right hemicolectomy for colon cancer presented with severe hypothyroidism and hoarseness 21 months after the operation.
  • Symptoms of hoarseness and neck swelling were already evident 4 months prior at which time tests for normal thyroid function were performed.
  • Core biopsy of the thyroid gland showed invasion of poorly differentiated adenocarcinoma cells.
  • There were multiple lung parenchymal nodules and adrenal masses at the time of evaluation.
  • The patient was started on palliative chemotherapy with thyroid hormone replacement and gradually became euthyroid.
  • From these findings and the clinical observations, thyroid metastasis with hypothyroidism developing acutely from metastatic colon adenocarcinoma was diagnosed.

  • MedlinePlus Health Information. consumer health - Hypothyroidism.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16714841.001).
  • [ISSN] 0918-8959
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 9002-71-5 / Thyrotropin; Q51BO43MG4 / Thyroxine
  •  go-up   go-down






Advertisement